Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
Earnings for Marksans Pharma Limited (MARKSANS.NS)
Earnings in 2023 (TTM): $50.16 M
According to Marksans Pharma Limited's latest financial reports the company's current earnings (TTM) are $50.16 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Marksans Pharma Limited
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $50.16 M | $37.15 M |
| 2022 | $39.99 M | $31.54 M |
| 2021 | $29.31 M | $21.86 M |
| 2020 | $35.79 M | $28.25 M |
| 2019 | $18.61 M | $14.3 M |
| 2018 | $12.35 M | $9.53 M |
| 2017 | $5.9 M | $3.9 M |
| 2016 | $1.84 M | $1.13 M |
| 2015 | $12.65 M | $9.3 M |
| 2014 | $18.46 M | $12.96 M |
| 2013 | $10.23 M | $8.52 M |
| 2012 | $5.16 M | $5.43 M |
| 2011 | $-20,725,739 | $-21,180,057 |
| 2010 | $-25,515,092 | $-26,438,924 |
| 2009 | $-1,092,705 | $-1,189,446 |
| 2008 | $-828,917 | $-989,531 |
| 2007 | $2.43 M | $1.86 M |
| 2006 | $1.1 M | $792.66 K |
| 2005 | $3.72 M | $2.71 M |
| 2004 | $2.97 M | $2.43 M |